Cytos Biotechnology AG of Switzerland said an influenza vaccine that it is co-developing with Singapore’s Agency for Science, Technology and Research has met its primary endpoint for immunogenicity in a Phase 1 study in Asian volunteers. ---Subscribe to MedNous to access this article--- Company News Clinical Research
